U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C14H19O2.Na
Molecular Weight 242.2892
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUTIBUFEN SODIUM

SMILES

[Na+].CCC(C([O-])=O)C1=CC=C(CC(C)C)C=C1

InChI

InChIKey=SJBWJHOBCVAGGD-UHFFFAOYSA-M
InChI=1S/C14H20O2.Na/c1-4-13(14(15)16)12-7-5-11(6-8-12)9-10(2)3;/h5-8,10,13H,4,9H2,1-3H3,(H,15,16);/q;+1/p-1

HIDE SMILES / InChI
Butibufen is a non-steroidal anti-inflammatory cyclooxygenase inhibitor with analgesic and antipyretic properties. The drug was investigated for the treatment of osteoarthritis, rheumatoid artritis, and other arthroses. It was marketed under tradenames Mijal and Butilopan but now is withdrawn from the market.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Patents
Name Type Language
BUTIBUFEN SODIUM
Common Name English
BENZENEACETIC ACID, .ALPHA.-ETHYL-4-(2-METHYLPROPYL)-, SODIUM SALT (1:1)
Preferred Name English
Code System Code Type Description
CAS
60682-24-8
Created by admin on Mon Mar 31 23:38:20 GMT 2025 , Edited by admin on Mon Mar 31 23:38:20 GMT 2025
PRIMARY
EPA CompTox
DTXSID40976119
Created by admin on Mon Mar 31 23:38:20 GMT 2025 , Edited by admin on Mon Mar 31 23:38:20 GMT 2025
PRIMARY
ECHA (EC/EINECS)
262-374-3
Created by admin on Mon Mar 31 23:38:20 GMT 2025 , Edited by admin on Mon Mar 31 23:38:20 GMT 2025
PRIMARY
FDA UNII
33KW1RW80I
Created by admin on Mon Mar 31 23:38:20 GMT 2025 , Edited by admin on Mon Mar 31 23:38:20 GMT 2025
PRIMARY
PUBCHEM
23674255
Created by admin on Mon Mar 31 23:38:20 GMT 2025 , Edited by admin on Mon Mar 31 23:38:20 GMT 2025
PRIMARY